Advancing Reproductive Health With Data Driven Drug Discovery

SCIENCE AT OUR CORE

Ovartix is a pioneering women’s health biotechnology company developing first-in-class therapeutics for reproductive disease.

Founded by world-leading experts in reproductive medicine, we use science-backed innovation, including pioneering multi-omics and cell engineering technologies to unlock novel biology and transform the women’s health treatment landscape.

Our two decades long groundbreaking research into ovarian biology gives us an unprecedented advantage for innovating across women’s health indications, resulting in first-in-class therapies.

From cause to cure:
At the intersection of data and cell engineering

At the core of our approach is our ovary-centric drug discovery platform that integrates human multi-omics data with proprietary human cell-engineered ovarian models to uncover novel targets at the root of ovarian dysfunction – the key driver of infertility and poor female health.

DISCOVERY

We are discovering novel biology to unlock transformational medicines for patients that need them.

VALIDATION

The most promising results are cross-validated with rigorous experimental evidence, producing integrated data-driven designs for first-in-class drugs.

FOCUS

We focus on diseases where our technology can add significant value and look for opportunities where there is validated translational path to clinic.

SOLVING BOTTLENECK

Unlocking women’s health R&D with the first-in-class drug discovery platform, solving gaps around the lack of data and disease models.

1 in 3 women suffer from conditions linked to ovarian dysfunction

$85B

OVARIAN HEALTH MARKET LOCKED

The lack of data, disease models and mechanistic insights into ovarian biology has hampered drug discovery leaving millions of women with no therapeutics for the root cause of the disease.

beyond symptom management

Most of the current solutions mask or treat symptoms without going into the root cause.

beyond reproduction

Poor ovarian health and age-related decline in ovarian function lead to: heart disease, bone density loss, neurocognitive decline, autoimmune and metabolic disorders.

5X

Ovaries age faster than any other organ and cease to function decades ahead of our lifespan.

longevity

Hormonal changes associated with menopause speed up cellular aging by ~6%, a similar magnitude as in diabetes.

beyond reproduction

Poor ovarian health and age-related decline in ovarian function lead to: heart disease, bone density loss, neurocognitive decline, autoimmune and metabolic disorders.

Pioneering drug discovery platform for women’s health: a human-first, data-driven approach

Human Omics Data
On 300,000 Women

High-Throughput
Ovarian Cell Models

Selection of in house 2D and 3D
cell-engineered ovarian models

Validated Drug Target

Our platform

Uniquely integrates four core pillars to decode disease mechanisms

Human
Multi-Omics Data

We use large-scale human multi-omics data to understand the basis of the disease, providing unprecedented access to biological knowledge previously unavailable in women's health. By integrating human-derived data, we significantly improve the probability and reduce time for successful drug discovery.

2D and 3D cell-engineered
ovarian models

OvartiX develops ovarian cell models that capture the complex biology of the female reproductive system with translational accuracy, producing and responding to hormones, and delivering disease-relevant phenotypes for drug discovery experimentation.

High-performance experimentation
and computation

Our lab integrates tissue profiling, single-cell and spatial transcriptomics, sequencing and target validation.

Whole organ and
whole-body systems

We validate therapeutic candidates in biological systems that closely mimic human conditions, improving translational success.

Our Platform

High-throughput screening capabilities that span across:

Gene Editing

Leverages CRISPR for edit genes at scale, enabling the rapid and unbiased identification of novel drug targets and pathways.

Compound Screen

Systematic screening of vast in-house and external compound libraries to identify potential drug candidates that modulate specific cellular processes and disease phenotypes.

Elevating women’s health to the forefront of global drug discovery

Our platform is competitive, rigorous and scalable.

HUMAN-CENTRIC

Drug mechanisms with human genetic support have 2-7 fold more chance to succeed

HYPOTHESIS FREE

Our in silico models discover gene-to-disease patterns, across the whole genome

OVARY CENTRIC

Nature of our data and disease models

High-Throughput

Enables screening of thousands of compounds and large-scale genetic perturbations

Orthogonal

Enables us to generate rich maps of disease aetiology

Go-No-Go

Quick prioritisation of promising therapeutic opportunities

Broad Applicability

Across diverse ovarian conditions

Diversified Business Model

Unlocks in-house drug discovery programs and collaboration opportunities with pharma

Supported By

Innovative approaches driving the next generation of women’s therapeutics

Our technology has applicability to a wide range of reproductive conditions, unlocking $85B market opportunity

Infertility

PCOS

Menopause

Ovarian Preservation

Reproductive Cancers

We are driven to elevate today’s standard of care to improve women's health, well-being and longevity.

Leveraging OvartiX platform, we are building an industry-leading pipeline of best-in-class and first-in-class therapeutic assets. We focus on indications with high unmet need.

We are currently progressing a program for infertility and starting to advance multiple additional discovery-stage projects.

Disease Indication

Target ID

Target Validation

Lead ID

Lead OP

IND Enabling

Phase 1/2

Phase 3

Infertility (OVX001)

PCOS

Ovarian ageing

Phase 3

Phase 1/2

IND Enabling

Lead OP

Lead ID

Target Validation

Target ID

Disease Indication

Infertility (OVX001)

PCOS

Ovarian ageing

Fertility treatments have increased 120% in two decades yet success rates stagnate at ~25% per cycle

OVX001: An innovative treatment that improves outcomes for IVF and egg freezing

We are pioneering a first-in-class non-hormonal approach that increases the number of harvested eggs per cycle, reducing hormonal stimuli and number of cycles needed for a successful pregnancy.